Precigen Q1 2024 Earnings Report

Precigen's financial results for Q1 2024 were reported, highlighting the pivotal Phase 2 study data of PRGN-2012 and the anticipation of a rolling BLA submission in the second half of 2024.

Key Takeaways

Precigen reported its Q1 2024 financial results, noting a decrease in total revenues and an increase in research and development expenses. The company is preparing for a potential commercial launch of PRGN-2012 in 2025 and is evaluating financing opportunities to strengthen its balance sheet.

Pivotal Phase 2 study data of PRGN-2012 for recurrent respiratory papillomatosis (RRP) will be presented at the 2024 ASCO Annual Meeting.

PRGN-2012 rolling BLA submission is anticipated in the second half of 2024, with commercial readiness activities underway for a potential launch in 2025.

Two trial-in-progress presentations for PRGN-2009 in combination with pembrolizumab for recurrent/metastatic cervical cancer and oropharyngeal cancer to be presented at ASCO.

Cash, cash equivalents, and short-term investments totaled $44.8 million as of March 31, 2024.

Total Revenue

$1.07M

Previous year: $1.85M